Maxicortan (Hydrocortisone Acetate)

Hydrocortisone acetate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This action suppresses the production of pro‑inflammatory cytokines and mediators while promoting anti‑inflammatory proteins, leading to decreased swelling, erythema and immune cell activity at the site of application.

The appropriate amount and frequency of Maxicortan are determined by the prescribing healthcare professional based on the severity of the skin condition, patient age and treatment area. Patients should follow the prescriber’s instructions and not exceed the recommended application.

Safety data for topical hydrocortisone acetate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Maxicortan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxicortan contains hydrocortisone acetate, a low‑ to medium‑potency corticosteroid. Compared with higher‑potency agents such as clobetasol, it offers a favorable safety profile for short‑term use on sensitive areas, while still providing effective anti‑inflammatory action for mild to moderate skin conditions.

Store Maxicortan at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Maxicortan is applied topically to the affected skin area. A thin layer should be spread gently and rubbed in until absorbed, typically once or twice daily as directed by the prescriber. Hands should be washed before and after application.

Serious risks include skin atrophy, secondary infections, allergic contact dermatitis and, with extensive or prolonged use, systemic adrenal suppression. Patients should report any unusual skin changes, signs of infection or systemic symptoms such as fatigue or dizziness to their healthcare provider.

Maxicortan should be avoided in individuals with known hypersensitivity to hydrocortisone acetate or any formulation components, on severely infected or ulcerated skin, and in patients receiving systemic corticosteroids where additive effects could be harmful, unless specifically directed by a physician.